- 专利标题: Stable cell lines for retroviral production
-
申请号: US16606281申请日: 2018-04-18
-
公开(公告)号: US11795474B2公开(公告)日: 2023-10-24
- 发明人: Conrad Vink
- 申请人: GlaxoSmithKline Intellectual Property Development Limited
- 申请人地址: GB Brentford
- 专利权人: GlaxoSmithKline Intellectual Property Development Limited
- 当前专利权人: GlaxoSmithKline Intellectual Property Development Limited
- 当前专利权人地址: GB Stevenage
- 代理商 Carly Shanahan
- 优先权: GB 06121 2017.04.18
- 国际申请: PCT/EP2018/059917 2018.04.18
- 国际公布: WO2018/192981A 2018.10.25
- 进入国家日期: 2019-10-18
- 主分类号: C12N15/00
- IPC分类号: C12N15/00 ; C12N15/86 ; C07K14/16
摘要:
The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.
公开/授权文献
- US20200095606A1 STABLE CELL LINES FOR RETROVIRAL PRODUCTION 公开/授权日:2020-03-26
信息查询
IPC分类: